{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-017722","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.606288+00:00","generated_at":"2026-06-27T15:21:14.027478+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaccinex reports 2 complete responses in first 3 patients in Phase 1b KEYNOTE-B84 study for HNSCC","bullets":["Two of three patients in Phase 1b safety segment achieved complete responses per RECIST v1.1.","Both responders had low PD-L1 expression (CPS<20); HPV-negative status.","Third patient had clinical progression and withdrew before week 9; SAEs attributed to pre-existing condition.","Expansion phase now open; will enroll up to 62 additional patients across 18 US sites.","Data safety monitoring board confirmed pepinemab (20 mg/kg Q3W) + KEYTRUDA (200 mg Q3W) well-tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-017722","json":"https://secwatch.observer/filing/0001193125-22-017722.json","markdown":"https://secwatch.observer/filing/0001193125-22-017722.md","text":"https://secwatch.observer/filing/0001193125-22-017722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522017722/0001193125-22-017722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522017722/d252591d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:21:14.027478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}